EMA recommends approval of abiraterone and ioflupane (123I) generics

Generics/News | Posted 07/05/2021 post-comment1 Post your comment

The European Medicines Agency’s (EMA) Committee for Medical Products for Human Use (CHMP) recommended granting marketing authorizations for two generic medicinal products at its April 2021 meeting.

52 MD002433

Abiraterone KRKA (abiraterone acetate)
The first product is Abiraterone KRKA (abiraterone acetate), for the treatment of adult men with metastatic prostate cancer. This drug treatment is for advanced prostate cancer and is most commonly offered to patients whose cancer has stopped responding to other types of hormone therapy. Abiraterone is a hormone antagonist that inhibits the production of androgens in the testes, adrenal glands and prostatic tumour tissues.

CHMP’s recommendation follows satisfactory studies that have demonstrated the quality of Abiraterone KRKA, and its bioequivalence to the reference originator product, Janssen-Cilag’s Zytiga. Abiraterone KRKA will be licensed for the same indications as Zytiga. It joins another generic of the product, Abiraterone Accord (abiraterone), which received a positive opinion towards the recommendation for approval by EMA in early 2021 [1].

Celsunax (ioflupane (123I)
In addition, Celsunax (ioflupane (123I)) also received CHMP’s recommendation. This product is a radioactive diagnostic tool with an originator product first developed by GE Healthcare [2]. This generic Celsunax is intended for detecting loss of functional dopaminergic neuron terminals in the striatum, this is relevant to the diagnosis of Parkinson’s disease and other related diseases and dementia [3].

Related articles
Generics companies winning the legal battle in the US

Way cleared in US for Suboxone and Zytiga generics

Generics applications under review by EMA July 2020

LATIN AMERICAN FORUM – Coming soon!

To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

 

LATIN AMERICAN FORUM – Próximamente!

Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

References
1. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of abiraterone and thiotepa generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 May 7]. Available from: www.gabionline.net/Generics/News/EMA-recommends-approval-of-abiraterone-and-thiotepa-generics 
2. GaBI Online - Generics and Biosimilars Initiative. Generics applications under review by EMA January 2021 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 May 7]. Available from: www.gabionline.net/Generics/General/Generics-applications-under-review-by-EMA-January-2021 
3. GaBI Online - Generics and Biosimilars Initiative. EMA approves hypertension and Parkinson’s generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 May 7]. Available from: www.gabionline.net/Generics/News/EMA-approves-hypertension-and-Parkinson-s-generics 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (1)
Post your comment
Posted 09/07/2025 by Ruben Alvin
Parkinson disease formula

My partner is 67 and has had Parkinson’s for around 3-4 years. It is a debilitating disease that only gets worse and needs some serious funding to find out 1 because the cure is out there. What causes it and 2. some better treatment for it which www .madibaherbalcenter. com have the guaranteed cure for PD. He takes over 13 weeks treatment from madiba herbal center formula that finally cure him, reverse all the symptoms including tremors ,as there is no-one available to help unless you have $4,000.00 per week to pay for a Nurse, but with this herbal system you can get rid of your Parkinson effectively ,he had tremors for several years and was gradually becoming worse before we found PD supplement from www .madibaherbalcenter. com on Facebook that was able to get rid of my husband PD disease and alleviate all symptoms within the short period of his usage.,they have the best medication for PD.They have given great relief to patients suffering from all types of diseases including :

1. COPD (Chronic Obstructive Pulmonary Disease)

2. HERPES 1/2

3. Parkinson’s

4. ALS (Lou Gehrig’s disease)

5. Hepatitis B

6. Emphysema

7. chronic pancreatitis

8. Bronchitis

9. Asthma

10.Acute angle-closure Glaucoma

11.ATRIAL FIBRILLATION

12.CHF

13.Cancer

14.Diabetes

15 Ankylosing Spondylitis

16.CREST Syndrome

17.Acid Reflux

18.Restrictive Lungs Disease

19.Crohn's Disease

20. Alzheimer's Disease

21.Stiff Person Syndrome (SPS)

22.Fibromyalgia

23.Bronchiectasis

24.HPV virus

25.Multiple Sclerosis (MS)

Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010